Toray Industries, Inc. (HQ: Chuo-ku, Tokyo; President: Akihiro Nikkaku; hereinafter referred to as “Toray”) announced today that it received approval from the U.S. Food and Drug Administration (FDA) to conduct Phase I clinical trials in the U.S. for nucleic acid medicine TRK-250 (Toray development code; BNC-1021: Bonac development code), which Toray has been co-developing with BONAC Corporation (HQ: Kurume City, Fukuoka; CEO: Hirotake Hayashi; hereinafter referred to as “BONAC”) for the treatment of idiopathic pulmonary fibrosis (“IPF").

 

For more details, please refer to the following documents.

 

Bonac will continue to promote research and development so that our nucleic acid chemistry technology will become a bridge to drug discovery.

 

Contact:

Corporate Affairs

press@bonac.co.jp

Toray Announces Initiation of Phase 1 Clinical Trial of TRK-250 for Patients with Idiopathic Pulmonary Fibrosis